Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 2

Vascular risk factors, cognitve decline, and dementia

Authors E Duron, Olivier Hanon

Published 11 April 2008 Volume 2008:4(2) Pages 363—381


E Duron, Olivier Hanon

Broca Hospital, Paris, France

Abstract: Dementia is one of the most important neurological disorders in the elderly. Aging is associated with a large increase in the prevalence and incidence of degenerative (Alzheimer’s disease) and vascular dementia, leading to a devastating loss of autonomy. In view of the increasing longevity of populations worldwide, prevention of dementia has turned into a major public health challenge. In the past decade, several vascular risk factors have been found to be associated with vascular dementia but also Alzheimer’s disease. Some longitudinal studies, have found significant associations between hypertension, diabetus mellitus, and metabolic syndrome, assessed at middle age, and dementia. Studies assessing the link between hypercholesterolemia, atrial fibrillation, smoking, and dementia have given more conflicting results. Furthermore, some studies have highlighted the possible protective effect of antihypertensive therapy on cognition and some trials are evaluating the effects of statins and treatments for insulin resistance. Vascular risk factors and their treatments are a promising avenue of research for prevention of dementia, and further long-term, placebo-controlled, randomized studies, need to be performed.

Keywords: dementia, hypertension, diabetus mellitus, hypercholesterolemia, metabolic syndrome

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Assessment of antitumor activity and acute peripheral neuropathy of 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016)

Ueno T, Endo K, Hori K, Ozaki N, Tsuji A, Kondo S, Wakisaka N, Murono S, Kataoka K, Kato Y, Yoshizaki T

International Journal of Nanomedicine 2014, 9:3005-3012

Published Date: 19 June 2014

Analyzing the behavior of a porous nano-hydroxyapatite/polyamide 66 (n-HA/PA66) composite for healing of bone defects

Xiong Y, Ren C, Zhang B, Yang H, Lang Y, Min L, Zhang W, Pei F, Yan Y, Li H, Mo A, Tu C, Duan H

International Journal of Nanomedicine 2014, 9:485-494

Published Date: 13 January 2014

Predictive value of visual evoked potentials, relative afferent pupillary defect, and orbital fractures in patients with traumatic optic neuropathy

Tabatabaei SA, Soleimani M, Alizadeh M, Movasat M, Mansoori MR, Alami Z, Foroutan AR, Joshaghani M, Safari S, Goldiz A

Clinical Ophthalmology 2011, 5:1021-1026

Published Date: 25 July 2011

Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update

Juan V Llau, Raquel Ferrandis, Pilar Sierra, et al

Vascular Health and Risk Management 2010, 6:855-867

Published Date: 29 September 2010

Cardiovascular disease in patients with chronic kidney disease

Julian Wright, Alastair Hutchison

Vascular Health and Risk Management 2009, 5:713-722

Published Date: 26 August 2009

Treatment of pediatric pulmonary hypertension

Amy Hawkins, Robert Tulloh

Vascular Health and Risk Management 2009, 5:509-524

Published Date: 3 June 2009

Arterial stiffness in insulin resistance: The role of nitric oxide and angiotensin II receptors

Divina G Brillante, Anthony J O’Sullivan, Laurence G Howes

Vascular Health and Risk Management 2009, 5:73-78

Published Date: 4 December 2008

Management of acute coronary syndromes with fondaparinux

Harm Wienbergen, Uwe Zeymer

Vascular Health and Risk Management 2007, 3:321-329

Published Date: 15 July 2007

Ximelagatran: direct thrombin inhibitor

Shir-Jing Ho, Tim A Brighton

Vascular Health and Risk Management 2006, 2:49-58

Published Date: 15 March 2006